Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation.
Irene
I
Cavattoni
Tatjana
T
Zabelina
Francis
F
Ayuk
Christine
C
Wolschke
Ulrike
U
Bacher
Axel
A
Zander
Nicolaus
N
Kröger
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000166:cytology*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000166:cytology*; D016393:Lymphoma, B-Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D000069283:Rituximab; D055502:Secondary Prevention; D033581:Stem Cell Transplantation / Q000379:methods*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab